Literature DB >> 9242714

Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.

J Gromada, W G Ding, S Barg, E Renström, P Rorsman.   

Abstract

The mechanisms by which glucagon-like peptide 1(7-36)amide (GLP-1[7-36]amide) potentiates insulin secretion were investigated by measurements of whole-cell K+ and Ca2+ currents, membrane potential, the cytoplasmic Ca2+ concentration ([Ca2+]i) and exocytosis in mouse pancreatic B-cells. GLP-1(7-36)amide (10 nM) stimulated glucose-induced (10 mM) electrical activity in intact pancreatic islets. The effect was manifested as a 34% increase in the duration of the bursts of action potentials and a corresponding 28% shortening of the silent intervals. GLP-1(7-36)amide had no effect on the electrical activity at subthreshold glucose concentrations (< or = 6.5 mM). In cultured B-cells, GLP-1(7-36)amide produced a decrease of the whole-cell ATP-sensitive K+ (KATP) conductance remaining at 5 mM glucose by approximately 30%. This effect was associated with membrane depolarization and the initiation of electrical activity. GLP-1(7-36)amide produced a protein-kinase-A-(PKA-) and glucose-dependent fourfold potentiation of Ca(2+)-induced exocytosis whilst only increasing the Ca2+ current marginally. The stimulatory action of GLP-1(7-36)amide on exocytosis was mimicked by the pancreatic hormone glucagon and exendin-4, a GLP-1 receptor agonist. Whereas the stimulatory action of GLP-1(7-36)amide could be antagonized by exendin-(9-39), this peptide did not interfere with the ability of glucagon to stimulate exocytosis. We suggest that GLP-1(7-36)amide and glucagon stimulate insulin secretion by binding to distinct receptors. The GLP-1(7-36)amide-induced stimulation of electrical activity and Ca2+ influx can account for (maximally) a doubling of insulin secretion. The remainder of its stimulatory action results from a cAMP/PKA-dependent potentiation of Ca(2+)-dependent exocytosis exerted at a stage distal to the elevation of [Ca2+]i.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242714     DOI: 10.1007/s004240050431

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  41 in total

1.  Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.

Authors:  Sebastian Steven; Kerstin Jurk; Maximilian Kopp; Swenja Kröller-Schön; Yuliya Mikhed; Kathrin Schwierczek; Siyer Roohani; Fatemeh Kashani; Matthias Oelze; Thomas Klein; Sergey Tokalov; Sven Danckwardt; Susanne Strand; Philip Wenzel; Thomas Münzel; Andreas Daiber
Journal:  Br J Pharmacol       Date:  2016-08-21       Impact factor: 8.739

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

3.  Islet alpha-cells do not influence insulin secretion from beta-cells through cell-cell contact.

Authors:  Helen Brereton; Melanie J Carvell; Shanta J Persaud; Peter M Jones
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

4.  A basic set of homeostatic controller motifs.

Authors:  T Drengstig; I W Jolma; X Y Ni; K Thorsen; X M Xu; P Ruoff
Journal:  Biophys J       Date:  2012-11-07       Impact factor: 4.033

5.  Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.

Authors:  Jacob D Brown; Danielle McAnally; Jennifer E Ayala; Melissa A Burmeister; Camilo Morfa; Layton Smith; Julio E Ayala
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-06-27       Impact factor: 3.619

Review 6.  A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion.

Authors:  Makoto Shigeto; Chae Young Cha; Patrik Rorsman; Kohei Kaku
Journal:  J Mol Med (Berl)       Date:  2017-01-17       Impact factor: 4.599

7.  Approach to the Patient with MODY-Monogenic Diabetes.

Authors:  David T Broome; Kevin M Pantalone; Sangeeta R Kashyap; Louis H Philipson
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

8.  Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass.

Authors:  Richard W Gelling; Patricia M Vuguin; Xiu Quan Du; Lingguang Cui; John Rømer; Raymond A Pederson; Margarita Leiser; Heidi Sørensen; Jens J Holst; Christian Fledelius; Peter B Johansen; Norman Fleischer; Christopher H S McIntosh; Erica Nishimura; Maureen J Charron
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

Review 9.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

10.  Functional characterization of N-terminally GFP-tagged GLP-1 receptor.

Authors:  Aljosa Bavec; Alenka Licar
Journal:  J Biomed Biotechnol       Date:  2009-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.